Most teams treat formulation patents like a black box. That’s why they miss the design-around window.
In pharma, the “real” competitive advantage often isn’t the active ingredient—it’s the formulation. Yet formulation patents are frequently approached …

Russia’s VED/SSM lists are often treated like a bureaucratic footnote. But for pharma companies, they’re closer to a market-access “switchboard”—and the timing of generic entry can be the difference between capturing share and watching competitors lock…

Pharma pipelines don’t fail because of science. They fail because of timing.
A single “surprise” patent, an unexpected exclusivity extension, or a licensing gap can turn a launch window into a scramble—complete with rework, renegotiations, and costly…

The “ANDA” playbook is getting crowded. The real edge may be the 505(b)(2) path.
If you’re building a differentiated drug in today’s regulatory environment, you’ve probably felt the pressure: crowded therapeutic classes, aggressive patent strategies, a…

🚨 Pharma IP teams: Russia’s patent-term extension landscape is shifting—and the window to get ahead of it is closing.
If you’re managing global portfolios, you already know the uncomfortable truth: patent strategy isn’t just about filing. It’s about…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
In pharma, “winning” a patent is often treated like a finish line. File. Prosecute. Get the grant. Move on.
But the market doesn’t reward paperwork—it rewa…

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical market, “patent expiration” isn’t just a legal milestone. It’s a procurement event. It’s a budget event. It’s a patient access event. And increasingl…

Generic launches don’t happen on a calendar—they happen when the patent landscape finally runs out.
Most teams still forecast generic entry like it’s a spreadsheet exercise: pull a few expiration dates, add a buffer, and hope. But in branded pharma, …

Most people “search” the Orange Book. The best people mine it.
If you’re in pharma business development, BD strategy, licensing, or competitive intelligence, you already know the FDA’s Orange Book is a goldmine. But most teams treat it like a static di…

Biotech R&D is awash in spreadsheets—but most portfolios still rank projects the way we used to: by scientific promise, not by financial reality.
That’s the problem. And it’s why two metrics—NPV (Net Present Value) and the Profitability Index (PI)—…